Expand ABCL Menu
ABCL MENU

ABCL Latest Press Releases

-- October 8, 2026 --

AbCellera Announces Presentation of Phase 1/2 Data for ABCL635 at TMS 2026 Annual Meeting Business Wire 4:05 PM

-- October 1, 2026 --

AbCellera to Report Third Quarter 2026 Financial Results on November 9, 2026 Business Wire 4:05 PM

-- September 16, 2026 --

AbCellera Announces Presentation of Phase 2 Data for ABCL635 at the IMS World Congress on Menopause 2026 Business Wire 4:05 PM

-- August 19, 2026 --

Most AI Drug Discovery Reads the Genetic Code. The Next Wave Is Learning to Read What the Code Actually Does. Globe Newswire 8:56 AM

-- August 13, 2026 --

AbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded Warrants Business Wire 12:05 AM

-- August 11, 2026 --

These Have the Market Hot Zone Catalysts and Setups Globe Newswire 4:52 PM
AbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants Business Wire 4:01 PM

-- August 10, 2026 --

The Catalysts are Back: Socket Mobile Breaks Out while Biotechs Race Toward Major Milestones Globe Newswire 10:39 AM
AI Found an Influenza Target That Survives Viral Mutation Globe Newswire 9:10 AM
AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635, Demonstrating Significant Reduction in Frequency and Severity of Vasomotor Symptoms and a Favorable Tolerability Profile Business Wire 7:00 AM

-- August 7, 2026 --

AbCellera to Announce Top-Line Results from the Phase 2 Trial of ABCL635 for the Treatment of Moderate-to-Severe VMS Due to Menopause on Monday, August 10, 2026 Business Wire 4:30 PM

-- August 5, 2026 --

AbCellera Reports Q2 2026 Business Results Business Wire 4:05 PM

-- July 29, 2026 --

AbCellera Announces Collaboration with Vertex to Discover Multispecific T-Cell Engagers for Autoimmune Diseases and Other Conditions Business Wire 7:00 AM

-- July 7, 2026 --

AbCellera to Report Second Quarter 2026 Financial Results on August 5, 2026 Business Wire 4:05 PM

-- July 6, 2026 --

AbCellera Appoints Dr. Lynn Seely to its Board of Directors Business Wire 9:00 AM

-- July 1, 2026 --

As AI Models Become Commodities, One Bio-Native AI Company Just Moved to Patent the Thing That Actually Compounds: the Data PRNewswire 9:01 AM

-- June 17, 2026 --

Jazz Pharmaceuticals and AbCellera Announce Collaboration to Discover Next-Generation T-cell Engaging Multispecific Antibodies Business Wire 7:00 AM

-- June 5, 2026 --

AbCellera Appoints Dr. Victor Sandor to its Board of Directors Business Wire 9:00 AM

-- May 11, 2026 --

AbCellera Reports Q1 2026 Business Results & Announces Positive Interim Phase 1 Clinical Data for ABCL635 Business Wire 4:05 PM
Market Data Delayed 15 Minutes